Aligos Therapeutics Stock Performance
| ALGS Stock | USD 8.39 0.27 3.33% |
The firm shows a Beta (market volatility) of -0.0573, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Aligos Therapeutics are expected to decrease at a much lower rate. During the bear market, Aligos Therapeutics is likely to outperform the market. At this point, Aligos Therapeutics has a negative expected return of -0.0043%. Please make sure to confirm Aligos Therapeutics' maximum drawdown, as well as the relationship between the accumulation distribution and price action indicator , to decide if Aligos Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Aligos Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable technical and fundamental indicators, Aligos Therapeutics is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 135.8 M | |
| Total Cashflows From Investing Activities | -18.3 M |
Aligos Therapeutics Relative Risk vs. Return Landscape
If you would invest 932.00 in Aligos Therapeutics on October 28, 2025 and sell it today you would lose (93.00) from holding Aligos Therapeutics or give up 9.98% of portfolio value over 90 days. Aligos Therapeutics is currently does not generate positive expected returns and assumes 5.8725% risk (volatility on return distribution) over the 90 days horizon. In different words, 52% of stocks are less volatile than Aligos, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aligos Therapeutics Target Price Odds to finish over Current Price
The tendency of Aligos Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 8.39 | 90 days | 8.39 | about 67.59 |
Based on a normal probability distribution, the odds of Aligos Therapeutics to move above the current price in 90 days from now is about 67.59 (This Aligos Therapeutics probability density function shows the probability of Aligos Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Aligos Therapeutics has a beta of -0.0573. This suggests as returns on the benchmark increase, returns on holding Aligos Therapeutics are expected to decrease at a much lower rate. During a bear market, however, Aligos Therapeutics is likely to outperform the market. Additionally Aligos Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Aligos Therapeutics Price Density |
| Price |
Predictive Modules for Aligos Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Aligos Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Aligos Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Aligos Therapeutics is not an exception. The market had few large corrections towards the Aligos Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Aligos Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Aligos Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.01 | |
β | Beta against Dow Jones | -0.06 | |
σ | Overall volatility | 1.49 | |
Ir | Information ratio | -0.01 |
Aligos Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Aligos Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Aligos Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Aligos Therapeutics generated a negative expected return over the last 90 days | |
| Aligos Therapeutics has high historical volatility and very poor performance | |
| Aligos Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.94 M. Net Loss for the year was (131.21 M) with loss before overhead, payroll, taxes, and interest of (65.8 M). | |
| Aligos Therapeutics currently holds about 159.34 M in cash with (80.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72. |
Aligos Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Aligos Stock often depends not only on the future outlook of the current and potential Aligos Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Aligos Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 6.3 M | |
| Cash And Short Term Investments | 56.9 M |
Aligos Therapeutics Fundamentals Growth
Aligos Stock prices reflect investors' perceptions of the future prospects and financial health of Aligos Therapeutics, and Aligos Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aligos Stock performance.
| Return On Equity | -1.42 | |||
| Return On Asset | -0.55 | |||
| Operating Margin | (38.27) % | |||
| Current Valuation | (43.06 M) | |||
| Shares Outstanding | 5.35 M | |||
| Price To Book | 0.70 X | |||
| Price To Sales | 18.88 X | |||
| Revenue | 3.94 M | |||
| EBITDA | (86.53 M) | |||
| Cash And Equivalents | 159.34 M | |||
| Cash Per Share | 3.72 X | |||
| Total Debt | 8.38 M | |||
| Debt To Equity | 0.1 % | |||
| Book Value Per Share | 11.67 X | |||
| Cash Flow From Operations | (80.74 M) | |||
| Earnings Per Share | (13.54) X | |||
| Total Asset | 70.09 M | |||
| Retained Earnings | (618.01 M) | |||
About Aligos Therapeutics Performance
Assessing Aligos Therapeutics' fundamental ratios provides investors with valuable insights into Aligos Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Aligos Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. The company was incorporated in 2018 and is headquartered in South San Francisco, California. Aligos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people.Things to note about Aligos Therapeutics performance evaluation
Checking the ongoing alerts about Aligos Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aligos Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aligos Therapeutics generated a negative expected return over the last 90 days | |
| Aligos Therapeutics has high historical volatility and very poor performance | |
| Aligos Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.94 M. Net Loss for the year was (131.21 M) with loss before overhead, payroll, taxes, and interest of (65.8 M). | |
| Aligos Therapeutics currently holds about 159.34 M in cash with (80.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72. |
- Analyzing Aligos Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aligos Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Aligos Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aligos Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aligos Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aligos Therapeutics' stock. These opinions can provide insight into Aligos Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.